Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.

The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.

A 19-year-old is concerned about long-term microneedling for hair loss and is unsure if it will remain effective as they age. They experienced side effects from topical finasteride and are considering whether to try it again in the future, while also dealing with body dysmorphia and stress.

The user has been using finasteride and dutasteride for hair loss but is experiencing low energy and motivation, possibly due to high prolactin levels. Despite treatment, hairline recession continues, and the user is considering the impact of low DHT levels on overall health and energy.

A 20-year-old female with PCOS is experiencing hair loss and excessive facial hair. She is using ketoconazole and caffeine shampoos, microneedling, and considering anti-androgens like finasteride, but is cautious about minoxidil due to facial hair concerns.

Nutrafol, a hair loss supplement, has limited and potentially biased research, with one study showing a 10% increase in hair count for women after 6 months but no significant results for men. The user concludes that cheaper, well-studied options like minoxidil may be more effective, especially for men, given the lack of evidence supporting Nutrafol.

A 28-year-old male with a family history of baldness is deciding whether to start finasteride now or wait for visible hair changes. He is considering starting finasteride immediately to proactively address potential hair loss.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The conversation is about a person's two-year hair regrowth progress using finasteride, minoxidil, ketoconazole, and microneedling. They are comparing their hair from April 21, 2022, to April 13, 2024.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.